Literature DB >> 15800820

[Comparison of different stool tests for the detection of cancer of the colon].

T Vogel1, C Driemel, A Hauser, A Hansmann, S Lange, M Jonas, G Möslein.   

Abstract

BACKGROUND AND
OBJECTIVE: Colonoscopy is the gold standard for the diagnosis of colonic neoplasia. Because of the low compliance, the discomfort of bowel preparation and the procedure itself and the (albeit small) risk of perforation or bleeding alternative procedures such as stool tests are being focused on. PATIENTS AND METHODS: After informed consent stool samples of 116 patients (44 male, 72 female, median age 47 years), scheduled for colonoscopy and 22 patients (17 m, 5 f, 69 y) with known colorectal cancer stool samples were collected. The samples were investigated by three methods: a biochemical (Guajak) test for fecal occult blood, an immunological test for fecal occult blood and a test determining the dimer pyruvat kinase M2 (tumor M2-PK).
RESULTS: Sensitivity for detection of colorectal cancer or polyps was 27 % and 10 % for the biochemical test, 91 % and 19 % for the immunological test and 77 % and 48 % for the M2-PK-test, respectively. Specificity was 89 %, 94 % and 72 %, respectively.
CONCLUSIONS: Both methods for detection of occult blood had a similar specificity. The sensitivity of the immunological test for the detection of colorectal cancer was significantly higher. The M2-PK-test had a markedly lower specificity in diagnosing cancer. Because of the low sensitivity for polyps the usefulness of stool tests is questionable. Reducing incidence and mortality of colorectal cancer should be achieved by colonoscopy, a recommendation that requires specific communication to the public.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15800820     DOI: 10.1055/s-2005-865100

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  8 in total

1.  Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT.

Authors:  Cristina Zaccaro; Ilaria Maria Saracino; Giulia Fiorini; Natale Figura; John Holton; Valentina Castelli; Valeria Pesci; Luigi Gatta; Dino Vaira
Journal:  Intern Emerg Med       Date:  2017-02-02       Impact factor: 3.397

2.  Fecal tumor M2 pyruvate kinase is not a specific biomarker for colorectal cancer screening.

Authors:  Yogesh M Shastri; Jürgen Stein
Journal:  World J Gastroenterol       Date:  2007-05-21       Impact factor: 5.742

3.  Perspectives of colorectal cancer screening in Germany 2009.

Authors:  Andreas Sieg; Kilian Friedrich
Journal:  World J Gastrointest Endosc       Date:  2009-10-15

4.  Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis.

Authors:  Carolin Tonus; Markus Sellinger; Konrad Koss; Gero Neupert
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

5.  The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.

Authors:  Yong Cheol Kim; Jeong Ho Kim; Dae Young Cheung; Tae Ho Kim; Eun Jung Jun; Jung-Whan Oh; Chang Whan Kim; Woo Chul Chung; Byung-Wook Kim; Sung Soo Kim; Jin Il Kim; Soo-Heon Park; Jae Kwang Kim
Journal:  Gut Liver       Date:  2015-09-23       Impact factor: 4.519

6.  The Diagnostic Accuracy of the M2 Pyruvate Kinase Quick Stool Test--A Rapid Office Based Assay Test for the Detection of Colorectal Cancer.

Authors:  Suresh Sithambaram; Ida Hilmi; Khean-Lee Goh
Journal:  PLoS One       Date:  2015-07-09       Impact factor: 3.240

7.  Comparison of faecal protein biomarkers' diagnostic accuracy for colorectal advanced neoplasms: a systematic review and meta-analysis.

Authors:  Atefeh Nasir Kansestani; Mohammad Erfan Zare; Qingchao Tong; Jun Zhang
Journal:  Sci Rep       Date:  2022-02-16       Impact factor: 4.379

8.  Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study.

Authors:  U Haug; S Hundt; H Brenner
Journal:  Br J Cancer       Date:  2008-06-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.